Topics
Glioblastoma | Treatment | Targeted therapy | Ipatasertib
Home > Publications > Topics > Glioblastoma > Treatment > Targeted therapy > Ipatasertib
Tiu C, Yau W, Silva D, Waldron N, Ameratunga M, Scaranti M, Biondo
A, Welsh L, Creak A, Jones TL, Martin AJ, Bridges L, Zachariou A,
Crespo M, Ferreira A, Riisnaes R, Gurel B, Figueiredo I, Bogdan D,
Yuan W, Morilla R, Swales K, Decordova S, Prout T, Parmar M,
Baikady B, Rata M, Blackledge M, Tunariu N, Benjamin P, Rich P,
Daly R, Hu X, Yap C, Vivanco I, Paschalis A, Sharp A, Banerji U,
Minchom A, de Bono J, Lopez J.
Phase I
trial of Ipatasertib plus Atezolizumab enhances PI3K/AKT pathway
immune responses in solid tumors and refractory glioblastoma.
Clin
Cancer Res. 2026 Apr 27. doi:
10.1158/1078-0432.CCR-25-4364. PMID:
42043781. Trial
registration ID: NCT03673787. ˍ